Alzheimer’s trials face the unique challenge of studying participants with cognitive decline, amid a move towards digital ...

Our Director of Research Dr Sheona Scales describes her four highlights from this year's Clinical Trials on Alzheimer's ...

A new Alzheimer’s test collects just a few drops of blood from a finger prick, which can be mailed to a lab for analysis.

Needham downgraded Biogen Inc (NASDAQ:BIIB), citing limited catalysts for the company over the next year. Alzheimer’s drug ...

That Thursday, for the first time, the European Medicines Agency (EMA) approved a drug that targets the cause — not just the ...

For now, after obtaining approval for early stages of cognitive decline and dementia, lecanemab and donanemab continue their ...

Lecanemab, a drug designed to slow the progression of early stage Alzheimer's will not be available to patients in Sweden for ...

Background In the CLARITY AD study, lecanemab was shown to reduce markers of amyloid and slow cognitive decline at 18 months in early Alzheimer’s disease (AD). Here, we report the initial findings ...

Needham analyst Ami Fadia downgraded Biogen (BIIB) to Hold from Buy.Don't Miss our Black Friday Offers:Discover the latest stocks recommended ...

A new outbreak of E. Coli infections is under investigation by the FDA. As a result, dozens of brands of organic carrots and organic baby carrots have been recalled. As of Nov. 17 one person had ...